Analyses de Données de Cytométrie

@article{pmid36387187,

title = {Mass cytometry analysis reveals attrition of naïve and anergized self-reactive non-malignant B cells in chronic lymphocytic leukemia patients},

author = {Thibault Andrieu and Paul Mondière and Pierre-Emmanuel Jouve and Sébastien Dussurgey and Victor Malassigné and Hugo Servanton and Lucille Baseggio and Frédéric Davi and Anne-Sophie Michallet and Thierry Defrance},

doi = {10.3389/fonc.2022.1020740},

issn = {2234-943X},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Front Oncol},

volume = {12},

pages = {1020740},

abstract = {Chronic Lymphocytic Leukemia (CLL) is characterized by the progressive accumulation of monoclonal mature B lymphocytes. Autoimmune complications are common in CLL occurring in up to a quarter of all patients during the course of the illness. Etiology of autoimmunity in CLL is unknown but it is widely admitted that the pathogenic auto-Abs do not originate from the tumoral clone but from the non-malignant B cell pool. This indicates that the developmental scheme of non-malignant B cells could also be perturbed in CLL patients. To address this question, we have designed a B cell-centered antibody panel and used time-of-flight mass cytometry to compare the residual non-malignant B cell pool of CLL patients with the peripheral B cell pool of age-matched healthy donors. We show that the non-malignant B cell compartment of the patients is characterized by profound attrition of naïve B cells and of a population of anergized autoreactive B cells, suggesting impaired B cell lymphopoeisis as well as perturbations of the B cell tolerance checkpoints.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Simon2021,

title = {A Proinflammatory Cytokine Network Profile in Th1/Type 1 Effector B Cells Delineates a Common Group of Patients in Four Systemic Autoimmune Diseases},

author = {Quentin Simon and Alexis Grasseau and Marina Boudigou and Laëtitia Le Pottier and Eléonore Bettachioli and Divi Cornec and Bénédicte Rouvière and Christophe Jamin and Lucas Le Lann and and and Maria Orietta Borghi and Rocio Aguilar‐Quesada and Yves Renaudineau and Marta E. Alarcón‐Riquelme and Jacques‐Olivier Pers and Sophie Hillion},

doi = {10.1002/art.41697},

issn = {2326-5205},

year  = {2021},

date = {2021-08-00},

urldate = {2021-08-00},

journal = {Arthritis & Rheumatology},

volume = {73},

number = {8},

pages = {1550--1561},

publisher = {Wiley},

abstract = {<jats:sec>

                    <jats:title>Objective</jats:title>

                    <jats:p>The effector T cell and B cell cytokine networks have been implicated in the pathogenesis of systemic autoimmune diseases, but the association of these cytokine networks with the heterogeneity of clinical manifestations and immune profiles has not been carefully examined. This study was undertaken to examine whether cytokine profiles can delineate distinct groups of patients in 4 systemic autoimmune diseases (systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis, and systemic sclerosis).</jats:p>

                  </jats:sec>

                  <jats:sec>

                    <jats:title>Methods</jats:title>

                    <jats:p>A total of 179 patients and 48 healthy volunteers were enrolled in the multicenter cross‐sectional PRECISE Systemic Autoimmune Diseases (PRECISESADS) study. Multi‐low‐dimensional omics data (cytokines, autoantibodies, circulating immune cells) were examined. Coculture experiments were performed to test the impact of the cytokine microenvironment on T cell/B cell cross‐talk.</jats:p>

                  </jats:sec>

                  <jats:sec>

                    <jats:title>Results</jats:title>

                    <jats:p>A proinflammatory cytokine profile defined by high levels of CXCL10, interleukin‐6 (IL‐6), IL‐2, and tumor necrosis factor characterized a distinct group of patients in the 4 systemic autoimmune diseases. In each disease, this proinflammatory cluster was associated with a specific circulating immune cell signature, more severe disease, and higher levels of autoantibodies, suggesting an uncontrolled proinflammatory Th1 immune response. We observed in vitro that B cells reinforce Th1 differentiation and naive T cell proliferation, leading to the induction of type 1 effector B cells and IgG production. This process was associated with an increase in CXCL10, IL‐6, IL‐2, and interferon‐γ production.</jats:p>

                  </jats:sec>

                  <jats:sec>

                    <jats:title>Conclusion</jats:title>

                    <jats:p>This composite analysis brings new insights into human B cell functional heterogeneity based on T cell/B cell cross‐talk, and proposes a better stratification of patients with systemic autoimmune diseases, suggesting that combined biomarkers would be of great value for the design of personalized treatments.</jats:p>

                  </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid33626291,

title = {Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial},

author = {Juliana Park and Sophia Archuleta and May-Lin Helen Oh and Lynette Pei-Chi Shek and Hao Wang and Matthew Bonaparte and Carina Frago and Alain Bouckenooghe and Frederique Jantet-Blaudez and Sarah Begue and Sophie Gimenez-Fourage and Anke Pagnon},

doi = {10.1080/21645515.2020.1861875},

issn = {2164-554X},

year  = {2021},

date = {2021-07-01},

urldate = {2021-07-01},

journal = {Hum Vaccin Immunother},

volume = {17},

number = {7},

pages = {2107--2116},

abstract = {The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who completed the 3-dose schedule >5 years previously (NCT02824198), demonstrated that a booster restored neutralizing antibody titers to post-dose 3 levels. We present additional immunogenicity assessments up to 24 months post-booster, and B- and T-cell responses in a participant subset. Participants aged 9-45 years that had received all three doses of CYD-TDV were randomized 3:1 to receive a booster dose of CYD-TDV (n = 89) or placebo (n = 29). Neutralizing antibody levels at Months 1, 6, 12, and 24 post-booster were assessed by plaque reduction neutralization test. In a subset, B-cell responses were assessed by a fluorescent immunospot assay, and T-cells analyzed by flow cytometry at Days 0, 7, 12, Months 1 and 12. We observed an increase of antibody titers Month 1 post-booster, then a gradual decline to Month 24. In the CYD-TDV booster group, an increase in plasmablasts was seen at Day 7 declining by Day 14, an increase in memory B-cells was observed at Day 28 with no persistence at Month 12. CYD-TDV booster recalled a CD8+ T-cell response, dominated by IFN-γ secretion, which decreased 12 months post-booster. This study showed a short-term increase in antibody titers and then gradual decrease following CYD-TDV booster injection >5 years after primary immunization, and the presence of memory B-cells activated following the booster, but with low persistence.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}